Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis

被引：17

作者：

Guadagno, Philip A. ^{[1
]}

Bellin, Erin G. Summers ^{[1
]}

Harris, William S. ^{[1
]}

Dayspring, Thomas D. ^{[2
]}

Hoefner, Daniel M. ^{[1
]}

Thiselton, Dawn L. ^{[1
]}

Stanovick, Brant ^{[1
]}

Warnick, G. Russell ^{[1
]}

McConnell, Joseph P. ^{[1
]}

机构：

[1] Hlth Diagnostic Lab Inc, Richmond, VA 23219 USA

[2] Fdn Hlth Improvement & Technol, Richmond, VA 23219 USA

来源：

CLINICA CHIMICA ACTA | 2015年 / 439卷

关键词：

Lipoprotein(a); Lipoprotein particles; Apo(a) isoform size; Cholesterol; Immunofixation; Electrophoresis; CARDIOVASCULAR-DISEASE; APOLIPOPROTEIN-B; INFLAMMATORY MARKERS; RISK-FACTOR; CHOLESTEROL; DENSITY; PLASMA; POLYMORPHISM; MANAGEMENT; LP(A);

D O I：

10.1016/j.cca.2014.10.013

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Background: Low-density lipoprotein (LDL) particle (P, or molar) concentration has been shown to be a more sensitive marker of cardiovascular disease (CVD) risk than LDL cholesterol. Although elevated circulating lipoprotein(a) [Lp(a)] cholesterol and mass have been associated with CV risk, no practicable method exists to measure Lp(a)-P. We have developed a method of determining Lp(a)-P suitable for routine clinical use. Methods: Lipoprotein immunofixation electrophoresis (Lipo-IFE) involves rigidly controlled electrophoretic separation of serum lipoproteins, probing with polyclonal apolipoprotein B antibodies, then visualization after staining with a nonspecific protein stain (Acid Violet). Lipo-IFE was compared to the Lp(a) mass assay for 1086 randomly selected patient samples, and for 254 samples stratified by apo(a) isoform size. Results: The Lipo-IFE method was shown to be precise (CV <10% above the 50 nmol/l limit of quantitation) and linear across a 16-fold range. Lipo-IFE compared well with the mass-based Lp(a) assay (r = 0.95), but was not affected by variations in apo(a) isoform size. With a throughput of 100 samples in 90 min, the assay is suitable for use in the clinical laboratory. Conclusions: The Lipo-IFE method will allow Lp(a)-P to be readily tested as a CVD risk factor in large-scale clinical trials. (C) 2014 The Authors. Published by Elsevier B.V.

引用

页码：219 / 224

页数：6

共 34 条

[1] Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein(a) method [J].